Neuroleptic malignant syndrome (NMS) is one of the rave but potentially fatal, idiosyncratic reaction to Neuroleptics and other medications (Smego and Durack, 1985). I t is characterised by fever, autonomic dysfunction, rigidity, altered conscious state with associated laboratory parameters like raised GPK, LDH, Hepatic enzymes, leucocytosis. This syndrome was first described by Delay and Denik...

Neuroleptic malignant syndrome (NMS) can be a severe condition requiring emergency treatment. Misdiagnosis or delay in treatment prove fatal. An unusual presentation of NMS is outlined patient being restarted on clozapine following mild COVID‐19 infection. A discussion explores its pathogenicity and the various ways it present clinically, which further illustrates atypical features this case.